Clinical trial
Growth Hormone in the Treatment of HIV-Associated Wasting
NCT00489528 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00489528 |
|---|---|
| Title | Growth Hormone in the Treatment of HIV-Associated Wasting |
| Official title | A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Wasting Syndrome |
| Intervention type | Drug |
| Interventions | Somatropin, Recombinant human growth hormone (r hGH) |
| Start date | Jul 1, 1997 |
| Completion | Mar 1, 2002 |
| First posted | Jun 21, 2007 |
| Last update posted | Oct 22, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: